Published in Clin Cancer Res on May 15, 2007
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol (2012) 3.36
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol (2009) 3.18
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut (2011) 2.14
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res (2009) 2.00
Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer (2014) 1.33
Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol (2011) 1.27
Treatment of malignant pheochromocytoma. Horm Metab Res (2009) 1.25
A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol (2010) 1.11
Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol (2012) 1.04
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer (2010) 1.02
Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy. BMC Cancer (2010) 1.01
Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nat Clin Pract Oncol (2009) 0.96
Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2014) 0.94
A multimodal approach to the management of neuroendocrine tumour liver metastases. Int J Hepatol (2012) 0.94
Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol (2012) 0.92
Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. Endocr Relat Cancer (2012) 0.92
Recent standardization of treatment strategy for pancreatic neuroendocrine tumors. World J Gastroenterol (2010) 0.91
Progress in the treatment of neuroendocrine tumors. Curr Oncol Rep (2009) 0.91
Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr Treat Options Oncol (2014) 0.89
A new era for the systemic therapy of neuroendocrine tumors. Oncologist (2012) 0.89
Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel. World J Gastroenterol (2010) 0.89
Typical bronchial carcinoid metastasizing to the brain: a case presentation. Case Rep Oncol (2011) 0.88
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. ScientificWorldJournal (2012) 0.86
Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors. Ann Surg (2014) 0.84
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer (2013) 0.84
Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report. J Thorac Oncol (2014) 0.84
Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist (2016) 0.84
Multidisciplinary management of advanced lung neuroendocrine tumors. J Thorac Dis (2015) 0.83
Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment. Ann Gastroenterol (2013) 0.83
Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors. Br J Cancer (2016) 0.81
Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations. Oncologist (2015) 0.80
A case of nonfunctioning pituitary carcinoma that responded to temozolomide treatment. Case Rep Endocrinol (2012) 0.80
Emerging therapies and latest development in the treatment of unresectable pancreatic neuroendocrine tumors: an update for clinicians. Therap Adv Gastroenterol (2013) 0.80
Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management. Ther Adv Med Oncol (2016) 0.79
Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus. Onco Targets Ther (2012) 0.79
O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents. Br J Cancer (2015) 0.79
Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma. Yale J Biol Med (2010) 0.79
Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET). PLoS One (2016) 0.79
Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor. World J Gastroenterol (2014) 0.78
Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib. Therap Adv Gastroenterol (2013) 0.78
Medical treatment of gastroenteropancreatic neuroendocrine tumors. Cancers (Basel) (2012) 0.78
Systemic therapy for advanced pancreatic neuroendocrine tumors. Semin Oncol (2013) 0.78
Treatment of pituitary carcinomas and atypical pituitary adenomas: a review. Neurol Med Chir (Tokyo) (2014) 0.77
Neuroendocrine tumors: is there a standard treatment? Gastrointest Cancer Res (2008) 0.77
Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors. Clin Cancer Res (2016) 0.77
Targeted therapy in advanced well-differentiated neuroendocrine tumors. Oncologist (2011) 0.77
Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Eur J Nucl Med Mol Imaging (2015) 0.77
Expression of O(6)-methylguanine DNA methyltransferase (MGMT) and its clinical significance in gastroenteropancreatic neuroendocrine neoplasm. Int J Clin Exp Pathol (2014) 0.76
The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors. Oncologist (2016) 0.76
Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors. Onco Targets Ther (2016) 0.75
Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies. EJNMMI Res (2015) 0.75
Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up. Arch Med Sci (2017) 0.75
The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids. Cancer Gene Ther (2016) 0.75
Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. J Transl Med (2016) 0.75
New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future. World J Gastrointest Oncol (2017) 0.75
Highly proliferative neuroendocrine carcinoma - influence of radiotherapy fractionation on tumor response. Radiat Oncol (2008) 0.75
Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors. BMC Cancer (2016) 0.75
Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors. Hematol Oncol Clin North Am (2015) 0.75
NETs: organ-related epigenetic derangements and potential clinical applications. Oncotarget (2016) 0.75
Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies. J Am Coll Surg (2012) 0.75
Sequential treatment in disseminated well- and intermediate-differentiated pancreatic neuroendocrine tumors: Common sense or low rationale? World J Clin Oncol (2016) 0.75
Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer. Mol Clin Oncol (2016) 0.75
MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas. Pituitary (2017) 0.75
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia (2017) 0.75
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. J Cancer Res Clin Oncol (2017) 0.75
Establishment of a tumor sphere cell line from a metastatic brain neuroendocrine tumor. Med Mol Morphol (2017) 0.75
Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 7.65
Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology (2007) 2.95
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol (2005) 2.69
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol (2011) 2.57
Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol (2010) 2.56
Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst (2003) 2.19
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology (2004) 2.16
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology (2012) 2.12
Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res (2008) 1.98
Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med (2014) 1.95
18F-FDG PET/CT Diagnosis of Bronchopulmonary Carcinoids Versus Pulmonary Hamartomas. Clin Nucl Med (2016) 1.94
Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. J Clin Endocrinol Metab (2013) 1.69
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol (2004) 1.62
Gastrinoma (duodenal and pancreatic). Neuroendocrinology (2007) 1.55
90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol (2010) 1.49
Assessment of inactive, active and mixed atherosclerotic plaques by 18F-FDG-PET; an age group-based correlation with cardiovascular risk factors. Int J Cardiovasc Imaging (2008) 1.45
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer (2011) 1.43
Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer (2007) 1.42
⁶⁸Ga-DOTA-TOC-PET/CT detects heart metastases from ileal neuroendocrine tumors. Endocrine (2013) 1.41
Recognizing genes differentially regulated in vitro by the multiple endocrine neoplasia type 1 (MEN1) gene, using RNA interference and oligonucleotide microarrays. Surgery (2006) 1.40
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology (2012) 1.38
Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg (2002) 1.35
NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas (2010) 1.31
Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod Pathol (2008) 1.30
Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging (2009) 1.30
Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology (2007) 1.26
Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med (2012) 1.24
Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta Oncol (2010) 1.23
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. Acta Oncol (2004) 1.23
Affinity of galectin-8 and its carbohydrate recognition domains for ligands in solution and at the cell surface. Glycobiology (2007) 1.21
Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology (2007) 1.21
Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab (2005) 1.18
PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci (2004) 1.17
Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report. J Clin Endocrinol Metab (2014) 1.15
Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol (2010) 1.15
Chemical characterization of brominated flame retardants and identification of structurally representative compounds. Environ Toxicol Chem (2006) 1.12
Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab (2007) 1.12
In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. Nucl Med Biol (2010) 1.12
[11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab (2006) 1.11
The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci (2002) 1.09
Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg (2012) 1.07
ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors. Neuroendocrinology (2010) 1.07
Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology (2007) 1.06
Positron emission tomography: a real-time tool to quantify early islet engraftment in a preclinical large animal model. Transplantation (2007) 1.05
Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol (2014) 1.05
Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg (2008) 1.05
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology (2009) 1.04
Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology (2009) 1.03
Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. Med J Aust (2010) 1.02
Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol (2010) 1.02
Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med (2013) 1.01
Mutational tuning of galectin-3 specificity and biological function. J Biol Chem (2010) 1.01
In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cell mass. Nucl Med Biol (2010) 1.01
Pancreatic tumours as part of the MEN-1 syndrome. Best Pract Res Clin Gastroenterol (2005) 1.00
Clinical testing for mutations in the MEN1 gene in Sweden: a report on 200 unrelated cases. J Clin Endocrinol Metab (2007) 0.98
High 18F-FDG Uptake in synthetic aortic vascular grafts on PET/CT in symptomatic and asymptomatic patients. J Nucl Med (2008) 0.97
Malignant gastric ghrelinoma with hyperghrelinemia. J Clin Endocrinol Metab (2004) 0.97
Quantitative imaging of serotonergic biosynthesis and degradation in the endocrine pancreas. J Nucl Med (2014) 0.97
A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A. Regul Pept (2004) 0.97
High success rate of parathyroid reoperation may be achieved with improved localization diagnosis. World J Surg (2008) 0.97
Menin's interaction with glial fibrillary acidic protein and vimentin suggests a role for the intermediate filament network in regulating menin activity. Exp Cell Res (2002) 0.96
High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol (2004) 0.96
Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol (2007) 0.95
Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med (2013) 0.95